Loading…

Axogen, Inc.AXGNCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of biologic products (nerve grafts, connectors, wraps) used by surgeons to repair damaged peripheral nerves.

Momentum leader 96
Mkt cap
$3.40B
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$110M
20-day average traded
Fwd P/E
87.3×
forward earnings
ROIC−WACC
-17.7 pp
WACC 11.1%
Hurdle
+38 pp
Req g minus delivered
Next earnings
97 days
23 Feb 2027
Close · USD$56.95
1D+2.9%
1W-2.9%
1M+57.5%
3M+22.6%
6M+33.4%
YTD+74.0%
1Y+141.6%
ATR %4.9%
Beta1.04
52w lowhigh4.6% off high

What Axogen does

Maker of biologic products (nerve grafts, connectors, wraps) used by surgeons to repair damaged peripheral nerves.

Sells directly to hospitals and surgery centres through its own sales force rather than distributors, and is paid per graft or connector used, so revenue follows the number of nerve-repair operations. The Avance graft, processed nerve tissue from human donors, is the larger product; Axoguard products wrap and protect a repaired nerve.

Products and services

  • Avance Nerve Graft
  • Axoguard nerve connectors/protectors
  • Nerve repair training/education services

Customers

  • Reconstructive/orthopedic/plastic surgeons
  • Hospitals

Where it sits in the supply chain

  • Medical devices/biologics
  • Peripheral nerve repair
  • Nerve grafts, connectors, protective…

What could go right

  • Peripheral nerve repair procedure growth
  • International market expansion

What could go wrong

  • Reimbursement/coverage risk
  • Niche market with limited scale

Moat: narrow (IP / patents, regulatory licence, brand). Category-leading, FDA-regulated processed nerve-graft products with limited direct biologic competitors.

Headquarters: Tampa, Florida · Founded: 1999 · Employees: 622

Named competitors

Axogen at a glance

Size Axogen (AXGN) is a United States Health Care company (Medical Specialties) with a market value of $3.40B, the 1451st largest of 3,085 United States companies the cockpit tracks. Shares closed at $56.95 on 18 Nov 2026.

Performance Over six months the shares gained 33.4%, against +3.2% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue grew 24.3% over the last twelve months (peer median +5.7%); the operating margin is -5.2% (peer median 8.3%).

Valuation It trades at 87.3× forward earnings against a peer median of 25.1× (3rd most expensive of 19).

Price implies For today's price to make sense, revenue must grow about 53% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is +38 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 17.7 points below its cost of capital (11.1% WACC).

Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026AXGN 138Peer median 104
Six months, rebased to 100: Axogen against the median of its 20 peers (local-currency closes).

Axogen financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$267M$225M$187M$159M$139M
Revenue growth—+20%+18%+15%—
Gross profit$198M$167M$142M$128M$114M
EBITDA-$4.42M$659,000$4.55M-$15.9M-$24.9M
Net income-$31.9M-$15.7M-$9.96M-$21.7M-$28.9M
Free cash flow$22.0M-$2.93M$1.43M-$19.6M-$36.1M
Capital expenditure$8.34M$5.59M$4.52M$14.9M$21.3M
Total debt$19.5M$67.6M$68.7M$69.3M$67.4M

Quarterly statements and history in the cockpit →

Axogen competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%0%+25%+50%PLSE603658TMDXAMBU-B6883014203603301TECN300003IRTC603014AFX1SXP688114NVST002432CDNAFIEATRCCOTNAXGN6-month return →1-month return →
Up and to the right = strong over both horizons. Axogen is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%0×100×200×603658TMDXAMBU-B6883014203603301TECN300003IRTCNVST002432CDNAATRCAXGNRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Axogen is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%0%50%603658TMDXAMBU-B603301TECN300003IRTC6030141SXP688114002432FIEATRCAXGNGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Axogen is the large dot.

Axogen competitors and peer comparison

Head to head with its named competitors (AXGN vs IART vs MDT vs BAX)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Axogen AXGN$3.40B+33%+24%-5%87.3×52.6%
Integra LifeSciences IART$1.08B-10%+1%12%6.0×5.9%
Medtronic MDT$129B+30%+10%20%16.8×9.1%
Baxter International BAX$13.5B+39%+5%6%12.7×13.4%
Stryker SYK$121B-1%+8%25%19.9×10.7%

How Axogen compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Axogen against its 20 peers (data as of 18 Nov 2026)
MeasureAXGNPeer medianRank in peer set
1-month return+57.5%-0.2%highest of 21
6-month return+33.4%+3.2%6th highest of 21
Distance from 52-week high-4.6%-24.1%3rd highest of 21
Revenue growth (TTM)+24.3%+5.7%5th highest of 21
Operating margin-5.2%8.3%4th lowest of 20
Forward P/E87.3×25.1×3rd most expensive of 19
Growth the price implies (Req g, 7 yrs)52.6%11.3%2nd most demanding of 17
Growth delivered (Del g)+14.9%+8.5%4th highest of 17
Hurdle (Req g minus delivered)+37.7 pp+1.2 pp4th most demanding of 17
ROIC minus cost of capital-17.7 pp-1.1 pplowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Axogen AXGNUnited States$3.40B+33%+24%-5%87.3×52.6%+14.9%
Pulse Biosciences PLSEUnited States$3.37B+76%+1,637%-5,821%n/an/an/a
Autobio Diagnostics 603658.SSChina$3.36B+16%+3%25%20.3×-0.4%+7.2%
TransMedics TMDXUnited States$3.35B+42%+28%12%43.4×38.4%+88.2%
Ambu A/S AMBU-B.CODenmark$3.47B+31%+7%13%28.8×10.0%+10.0%
iRay Technology 688301.SSChina$3.31B-30%+58%24%25.7×n/an/a
Sumitomo Bakelite 4203.TJapan$3.50B+7%+15%13%15.9×8.6%+8.9%
Zhende Medical 603301.SSChina$3.26B-10%+8%7%42.5×22.9%-16.1%
Tecan TECN.SWSwitzerland$3.60B+59%-4%1%35.5×45.4%+3.8%
Lepu Medical Technology (Beijing) 300003.SZChina$3.20B-13%-1%13%24.4×8.7%-4.2%
iRhythm IRTCUnited States$3.19B-19%+22%5%99.8×46.9%+23.0%
Shandong Weigao Blood Purification Products 603014.SSChina$3.63B-1%+4%n/a20.4×-1.2%+8.1%
Carl Zeiss Meditec AFX.DEGermany$3.17B+22%0%8%24.4×12.5%+10.8%
SCHOTT Pharma AG & Co. KGaA 1SXP.DEGermany$3.73B+32%+4%15%23.0×12.7%+11.0%
MGI Tech 688114.SSChina$3.06B-4%+2%-7%n/a43.7%-0.1%
Envista NVSTUnited States$3.81B0%+10%12%14.7×4.8%+7.1%
Andon Health 002432.SZChina$3.86B-24%-30%-26%16.1×-6.6%-7.4%
CareDx CDNAUnited States$3.91B+252%+39%1%50.6×n/an/a
Fielmann FIE.DEGermany$3.92B-3%+3%14%17.1×-5.5%+11.3%
AtriCure ATRCUnited States$2.82B+91%+14%3%212.4×54.2%+20.9%
COMET COTN.SWSwitzerland$2.78B-15%-3%6%32.8×n/an/a

Questions

Who are Axogen's main competitors?
Named competitors: Integra LifeSciences (IART), Medtronic (MDT), Baxter International (BAX), Stryker (SYK). The cockpit's measured peer set (industry) also includes Pulse Biosciences (PLSE), Autobio Diagnostics (603658.SS), TransMedics (TMDX), Ambu A/S (AMBU-B.CO), iRay Technology (688301.SS), Sumitomo Bakelite (4203.T).
Is Axogen expensive compared with its peers?
On forward p/e it trades at 87.3× against a peer median of 25.1×, 3rd most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about 53% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is +38 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Axogen stock performed?
Over six months to 18 Nov 2026 the shares returned +33.4% against +3.2% for the median peer; over one year +141.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.